These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
128 related articles for article (PubMed ID: 37536040)
1. Synchronous targeted delivery of TGF-β siRNA to stromal and tumor cells elicits robust antitumor immunity against triple-negative breast cancer by comprehensively remodeling the tumor microenvironment. Yang M; Qin C; Tao L; Cheng G; Li J; Lv F; Yang N; Xing Z; Chu X; Han X; Huo M; Yin L Biomaterials; 2023 Oct; 301():122253. PubMed ID: 37536040 [TBL] [Abstract][Full Text] [Related]
2. The programmed site-specific delivery of LY3200882 and PD-L1 siRNA boosts immunotherapy for triple-negative breast cancer by remodeling tumor microenvironment. Zhang P; Qin C; Liu N; Zhou X; Chu X; Lv F; Gu Y; Yin L; Liu J; Zhou J; Huo M Biomaterials; 2022 May; 284():121518. PubMed ID: 35462305 [TBL] [Abstract][Full Text] [Related]
3. Codelivery of Shikonin and siTGF-β for enhanced triple negative breast cancer chemo-immunotherapy. Li J; Zhao M; Liang W; Wu S; Wang Z; Wang D J Control Release; 2022 Feb; 342():308-320. PubMed ID: 35031387 [TBL] [Abstract][Full Text] [Related]
4. Anti-TGF-β/PD-L1 bispecific antibody promotes T cell infiltration and exhibits enhanced antitumor activity in triple-negative breast cancer. Yi M; Wu Y; Niu M; Zhu S; Zhang J; Yan Y; Zhou P; Dai Z; Wu K J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36460337 [TBL] [Abstract][Full Text] [Related]
5. Co-Delivery Nanomicelles for Potentiating TNBC Immunotherapy by Synergetically Reshaping CAFs-Mediated Tumor Stroma and Reprogramming Immunosuppressive Microenvironment. Zhang Y; Han X; Wang K; Liu D; Ding X; Hu Z; Wang J Int J Nanomedicine; 2023; 18():4329-4346. PubMed ID: 37545872 [TBL] [Abstract][Full Text] [Related]
6. TGF-β inhibition combined with cytotoxic nanomedicine normalizes triple negative breast cancer microenvironment towards anti-tumor immunity. Panagi M; Voutouri C; Mpekris F; Papageorgis P; Martin MR; Martin JD; Demetriou P; Pierides C; Polydorou C; Stylianou A; Louca M; Koumas L; Costeas P; Kataoka K; Cabral H; Stylianopoulos T Theranostics; 2020; 10(4):1910-1922. PubMed ID: 32042344 [TBL] [Abstract][Full Text] [Related]
7. Colocalized targeting of TGF-β and PD-L1 by bintrafusp alfa elicits distinct antitumor responses. Lan Y; Yeung TL; Huang H; Wegener AA; Saha S; Toister-Achituv M; Jenkins MH; Chiu LY; Lazorchak A; Tarcic O; Wang H; Qi J; Locke G; Kalimi D; Qin G; Marelli B; Yu H; Gross AW; Derner MG; Soloviev M; Botte M; Sircar A; Ma H; Sood VD; Zhang D; Jiang F; Lo KM J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35858707 [TBL] [Abstract][Full Text] [Related]
8. Aptamer targeted therapy potentiates immune checkpoint blockade in triple-negative breast cancer. Camorani S; Passariello M; Agnello L; Esposito S; Collina F; Cantile M; Di Bonito M; Ulasov IV; Fedele M; Zannetti A; De Lorenzo C; Cerchia L J Exp Clin Cancer Res; 2020 Sep; 39(1):180. PubMed ID: 32892748 [TBL] [Abstract][Full Text] [Related]
9. Targeting the cancer-associated fibroblasts as a treatment in triple-negative breast cancer. Takai K; Le A; Weaver VM; Werb Z Oncotarget; 2016 Dec; 7(50):82889-82901. PubMed ID: 27756881 [TBL] [Abstract][Full Text] [Related]
10. TGF-β blockade-improved chemo-immunotherapy with pH/ROS cascade-responsive micelle via tumor microenvironment remodeling. Dai L; Li X; Zheng X; Fu Z; Yao M; Meng S; Zhang J; Han B; Gao Q; Chang J; Cai K; Yang H Biomaterials; 2021 Sep; 276():121010. PubMed ID: 34247042 [TBL] [Abstract][Full Text] [Related]
11. Dual targeting of TGF-β and PD-L1 via a bifunctional anti-PD-L1/TGF-βRII agent: status of preclinical and clinical advances. Lind H; Gameiro SR; Jochems C; Donahue RN; Strauss J; Gulley JL; Palena C; Schlom J J Immunother Cancer; 2020 Feb; 8(1):. PubMed ID: 32079617 [TBL] [Abstract][Full Text] [Related]
12. Synergistic efficacy of simultaneous anti-TGF-β/VEGF bispecific antibody and PD-1 blockade in cancer therapy. Niu M; Yi M; Wu Y; Lyu L; He Q; Yang R; Zeng L; Shi J; Zhang J; Zhou P; Zhang T; Mei Q; Chu Q; Wu K J Hematol Oncol; 2023 Aug; 16(1):94. PubMed ID: 37573354 [TBL] [Abstract][Full Text] [Related]
13. The construction, expression, and enhanced anti-tumor activity of YM101: a bispecific antibody simultaneously targeting TGF-β and PD-L1. Yi M; Zhang J; Li A; Niu M; Yan Y; Jiao Y; Luo S; Zhou P; Wu K J Hematol Oncol; 2021 Feb; 14(1):27. PubMed ID: 33593403 [TBL] [Abstract][Full Text] [Related]
14. Adaptive antitumor immune response stimulated by bio-nanoparticle based vaccine and checkpoint blockade. Bai X; Zhou Y; Yokota Y; Matsumoto Y; Zhai B; Maarouf N; Hayashi H; Carlson R; Zhang S; Sousa A; Sun B; Ghanbari H; Dong X; Wands JR J Exp Clin Cancer Res; 2022 Apr; 41(1):132. PubMed ID: 35392977 [TBL] [Abstract][Full Text] [Related]
15. Relaxin-encapsulated polymeric metformin nanoparticles remodel tumor immune microenvironment by reducing CAFs for efficient triple-negative breast cancer immunotherapy. Zhang H; Chen L; Zhao Y; Luo N; Shi J; Xu S; Ma L; Wang M; Gu M; Mu C; Xiong Y Asian J Pharm Sci; 2023 Mar; 18(2):100796. PubMed ID: 37008735 [TBL] [Abstract][Full Text] [Related]
16. Dual inhibition of TGF-β and PD-L1: a novel approach to cancer treatment. Gulley JL; Schlom J; Barcellos-Hoff MH; Wang XJ; Seoane J; Audhuy F; Lan Y; Dussault I; Moustakas A Mol Oncol; 2022 Jun; 16(11):2117-2134. PubMed ID: 34854206 [TBL] [Abstract][Full Text] [Related]
17. Regulating the immunosuppressive tumor microenvironment to enhance breast cancer immunotherapy using pH-responsive hybrid membrane-coated nanoparticles. Gong C; Yu X; Zhang W; Han L; Wang R; Wang Y; Gao S; Yuan Y J Nanobiotechnology; 2021 Feb; 19(1):58. PubMed ID: 33632231 [TBL] [Abstract][Full Text] [Related]
18. Cancer stem cells in immunoregulation and bypassing anti-checkpoint therapy. Rouzbahani E; Majidpoor J; Najafi S; Mortezaee K Biomed Pharmacother; 2022 Dec; 156():113906. PubMed ID: 36306594 [TBL] [Abstract][Full Text] [Related]
19. Multifunctional nanodrug performs sonodynamic therapy and inhibits TGF-β to boost immune response against colorectal cancer and liver metastasis. Huang S; Ding D; Lan T; He G; Ren J; Liang R; Zhong H; Chen G; Lu X; Shuai X; Wei B Acta Biomater; 2023 Jul; 164():538-552. PubMed ID: 37037269 [TBL] [Abstract][Full Text] [Related]
20. Functionalized biomimetic nanoparticles combining programmed death-1/programmed death-ligand 1 blockade with photothermal ablation for enhanced colorectal cancer immunotherapy. Xiao Y; Zhu T; Zeng Q; Tan Q; Jiang G; Huang X Acta Biomater; 2023 Feb; 157():451-466. PubMed ID: 36442821 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]